259 results about "Atherosclerosis aorta" patented technology

A device, system and method for the generation of therapeutic acoustic shock waves for at least partially separating a deposit from a vascular structure. The shock waves may optionally be generated according to any mechanism which is known in the art, including but not limited to, spark gap technology, electromagnetic shock wave generation and piezoelectric technology for generating therapeutic pressure pulses. Examples of deposits which may be treated with the present invention include, but are not limited to, atherosclerotic plaques, any type of clot, and any type of thrombus or embolus. The vascular structure itself may be any such structure for conducting blood flow, including but not limited to arteries, veins and the aortic arch.

The invention discloses a SgRNA (single chain guide ribonucleic acid) of the exon 2 of a specific targeted ApoE gene. The nucleotide sequence of the SgRNA is GCTTCTGGGATTACCTGCGC. The invention also discloses an ApoE-CRISPR/Cas9 carrier containing the SgRNA and application of the ApoE-CRISPR/Cas9 carrier to structuring ApoE gene knockout mammal models and to preparing ApoE gene knockout kits. TheApoE-CRISPR/Cas9 carrier structures the ApoE gene knockout mammal models; ApoE gene knockout can affect in vivo lipid metabolism of mammals and accelerate the pathogenic processes of lipid metabolismcorrelated diseases such as atherosclerosis to further accelerate the modeling process of corresponding mammal disease models and provide animal experiment basis for research on diseases such as atherosclerosis.

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

A lipid-lowering tea and a production method relate to the production process of bagged tea. The invention mainly comprises raw hawthorns, cassia seeds, lotus leaves and black tea. The invention can obviously inhibit the increase of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and atherosclerosis index (CAI) of serum, improve the high-density lipoprotein cholesterol (HDL-C) and anti-atherogenic index (AI), prevent fatty liver degeneration, slow and inhibit the formation of atherosclerotic plaque. The tea is of food class, which ensures the taste and has the specific effect; long-term tea drinking causes no toxic side effects; besides, the lipid-lowering tea is convenient and can be used in daily life, working, tourism and leisure time, and the user can enjoy health-care in tea drinking.

The invention discloses a traditional Chinese medicine composition for treating hypertension and/or atherosclerosis, and relates to the technical field of traditional Chinese medicines. Aiming at the defects that overall effective treatment is in shortage in hypertension and/or atherosclerosis at present while recurrence is easily generated in chemical treatment, and the curative effect cannot last in the prior art, the traditional Chinese medicine composition for treating hypertension is prepared from the following raw materials in parts by weight: 10-20 parts of rhizoma alismatis, 12-18 parts of peach kernel, 6-10 parts of semen cassia, 10-15 parts of cynanchum paniculatum, 10-20 parts of ligusticum wallichii, 12-16 parts of mother chrysanthemum, 6-9 parts of root of red-rooted salvia, 20-30 parts of fructus aurantii, 20-30 parts of hawthorn, 10-16 parts of radix bupleuri, 12-18 parts of tuckahoe, 15-25 parts of scutellaria baicalensis, 10-20 parts of tribulusterrestris, 6-12 parts of radix paeoniae alba, 15-20 parts of rhodiola rosea and 10-15 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention has a good treatment effect in the aspects of treatment of hypertension and/or atherosclerosis, especially on a sufferer with atherosclerosis and hypertension, and has significant clinical popularization value.

The present invention discloses a traditional Chinese medicine composition for treating atherosclerosis, and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicines: milkvetch root, cordyceps sinensis, cynanchum otophyllum, radix rehmanniae preparata, cortex moutan, campsis grandiflora, semen vaccariae, angelica, panax notoginseng, semen raphani, gynostemma pentaphyllum, jujube, fallopia multiflora (thunb.) harald, Chinese wolfberry, taxillus sutchuenensis (lecomte) danser, tuckahoe, pericarpium citri reticulatae, alisma orientalis, prunella vulgaris l, apocynum venetum, eucommia ulmoides, curcuma longa l, hawthorn, safflower, gingko, sophora flower, semen cassiae, achyranthes bidentata, clematis chinensis, aloe, leeches, coix seed and licorice root. According to the present invention, after the medicines are combined, the synergetic efficacy is provided, such that the rapid and effective atherosclerosis treatment purpose is achieved, wherein the total efficiency can achieve 98.5%.

The invention discloses application of long non coding RNA (lncRNA) and interfering RNA thereof to treatment on atherosclerosis. Through high-throughput sequencing on an aortic tissue of an atherosclerosis mouse model, the invention discovers that the expression of lncRNA molecules in normal and late atherosclerosis mice is obviously different; and meanwhile, the lncRNA molecules are highly expressed in the atherosclerosis tissue and the lncRNA molecules are named as lncRNA-AFIAR. The experiment proves that the lncRNA-AFIAR has the functions of enhancing proliferation of macrophages, inhibiting macrophage apoptosis and the like and participates in the process of promoting the progress of the atherosclerosis. The aims of inhibiting the proliferation of the macrophages and reducing plaque formation can be fulfilled by inhibiting the lncRNA-AFIAR, so that the aim of inhibiting the progress of the AS. Therefore, the invention provides new molecular markers and intervention targets for diagnosing and treating the atherosclerosis and also provides new technical means for treating the atherosclerosis.

The invention relates to a multifunctional balloon catheter integrated with a puncture needle and a system. The balloon catheter adopting unique design and the system can be used for different types of tumor such as benign and malignant bile duct stenosis, esophagus cancer, colorectal cancer, bronchogenic carcinoma, gastric antrum cancer, portal vein and vena cava tumor thrombus of primary hepatic carcinoma and the like, a far-end part where an eccentric balloon and the puncture needle are located is precisely put in the part where tumor of a lumen is located, a swelling balloon pushes the far end of the puncture needle to attach to the tumor, a near end of a rotating system operates a nut of the system and pushes the puncture needle to extend out of the catheter, the far end of the puncture needle with shape memory is bent and punctures the tumor, the puncture needle can be used for injecting a tumor treatment drug into the tumor to treat tumor or sucking tissue for biopsy or is used as a radiofrequency ablation electrode to perform radiofrequency ablation/heating to treat the tumor; on the basis of the system, with the adoption of different designs, the multifunctional balloon catheter can be used for injection of the treatment drug into atherosclerosis plaques and treatment of aortic dissecting aneurysm.

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A³ is a substituted phenyl group or indanyl group. Formula (I).

Quinoline and quinoxaline compounds of formula I and III, wherein the substituents are as defined in claims 1 and 15, pharmaceutical compositions comprising these compounds and these compounds are effective in raising certain plasma lipid levels, including high-density lipoprotein cholesterol As well as the application of lowering certain other blood lipid levels such as LDL-cholesterol and triglycerides, thus for the treatment of diseases caused by abnormalities of low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides in mammals, including humans, such as Atherosclerosis and cardiovascular disease.

Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A¹ and A² are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring, and Z is an aromatic or heterocyclic ring.